Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events
LSTA 10.31.2024
About Gravity Analytica
Recent News
- 01.23.2025 - Lisata Therapeutics and WARPNINE Announce Encouraging Preliminary Results from the Phase 1b/2a iLSTA Trial Evaluating Certepetide in Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma
- 01.22.2025 - 2025 Sequire Investor Summit
- 01.22.2025 - Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma
Recent Filings
BASKING RIDGE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that management will participate at the following events in November:
BIO-Europe (November 4-6, 2024; Virtual: November 12-13, 2024)Format:In-person/VirtualLocation:Stockholm, SwedenLisata representative:Tariq Imam, Vice President of Business Development and Operations and Corporate Counsel at Lisata
Mr. Imam will be participating in one-on-one meetings at this event. If interested in meeting, please send a meeting request through the online partnering platform. For more information on BIO-Europe and how to register, pleaseclick hereor contactEBDcustomerservice@ebdgroup.com.
PEGS Europe Summit (November 5-7, 2024)Format: In-personLocation: Barcelona, SpainPresentation Date: Tuesday, November 5, 2024Presentation Time: 3:20 p.m. CESTPresenter: David J. Mazzo, PhD, President and Chief Executive Officer at Lisata
For more information on PEGS Europe and how to register, pleaseclick here.
LSX Inv€$tival showcase 2024 (November 18, 2024)Format: In-personLocation: Tobacco Dock, UKPresentation Date: Monday, November 18, 2024Presentation Time: 1:00 p.m. GMTPresenter: David J. Mazzo, PhD, President and Chief Executive Officer of Lisata
For more information on the LD Micro Main Event and how to register, pleaseclick hereor contactsteph@lsxleaders.com.
About Lisata Therapeutics
Lisata Therapeutics is aclinical-stage pharmaceutical companydedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s internalizing RGD, or Arginylglycylaspartic acid, (iRGD) cyclic peptide product candidate,certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on itsCendR Platform® technology. The Company expects to announce numerous milestones over the next 1.5 years and believes that its projected capital will fund operations into early 2026, encompassing anticipated data milestones from its ongoing and planned clinical trials. Learn more aboutcertepetide’s mechanism of action in our short film. For more information on the Company, please visitwww.lisata.com.
Contact:
Investors:Lisata Therapeutics, Inc.John MendittoVice President, Investor Relations and Corporate CommunicationsPhone: 908-842-0084Email: jmenditto@lisata.com
Media:ICR HealthcareElizabeth ColemanSenior AssociatePhone: 203-682-4783Email: elizabeth.coleman@westwicke.com
